Heart failure & cardiomyopathies
Finerenone and Cardiovascular Outcomes According to Baseline Kidney Function in Patients With Heart Failure: The FINEARTS-HF Trial
Authors' conclusion
In the FINEARTS-HF trial (where the target dose of finerenone was determined by baseline kidney function), the effect of finerenone to reduce the composite of cardiovascular death and total HF events did not significantly differ across a range of baseline eGFR and UACR.
Study context
- Population
- Patients with heart failure (HF) with mildly reduced or preserved EF
- Comparison
- Finerenone vs placebo
- Primary endpoint
- Total HF events and CV death, by baseline eGFR and UACR
Methodological detailsglobal, subgroup analysis by baseline kidney function
- Global
- Subgroup analysis by baseline kidney function
Primary result
As reported in the abstract
Finerenone vs PlaceboRate ratio (95% CI)
eGFR ≥60 mL/min/1.73 m²: 9.2vs 12.5 per 100 patient-years
0.72(0.59–0.88)
eGFR 45 to <60 mL/min/1.73 m²: 16.5vs 19.9 per 100 patient-years
0.83(0.65–1.06)
eGFR <45 mL/min/1.73 m²: 28.0vs 28.0 per 100 patient-years
1.02(0.83–1.26)
Further findings
Total worsening HF events, by baseline estimated glomerular filtration rate (eGFR)
- Similar results to primary endpoint
Composite cardiovascular (CV) outcome, by baseline urine albumin-creatinine ratio (UACR)
- Finerenone lowered risk similarly across UACR categories
- Interaction P = 0.48
Original publication
Finerenone and Cardiovascular Outcomes According to Baseline Kidney Function in Patients With Heart Failure: The FINEARTS-HF Trial. JACC Heart Fail. Published 5 December 2025. doi:10.
Composed by AI from the published abstract and checked against it. How Briefs are made →